Dihydroergotamine: Role in the treatment of migraine

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 9, 2009, Pages 1141-1148

  Schürks, Markus ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CGRP receptor antagonists; Dihydroergotamine; Ergotamine; Migraine; Triptans

Indexed keywords

DIHYDROERGOTAMINE; NOSE SPRAY; PLACEBO; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ANALGESIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEADACHE; HEART MUSCLE FIBROSIS; HUMAN; INJECTION SITE PAIN; LUNG FIBROSIS; MIGRAINE; NAUSEA AND VOMITING; PAIN; REVIEW;

CLINICAL TRIALS AS TOPIC; DIHYDROERGOTAMINE; HUMANS; MIGRAINE DISORDERS;

EID: 70249143654     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903164211     Document Type: Review

References (63)

1. Silberstein SD. Migraine. Lancet 2004;363:381-391
2. Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006;5:148-157
3. Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med 2005;118(Suppl 1):3S-10S
4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762 (Pubitemid 30727712)
5. Evers S, May A, Fritsche G, et al. Akuttherapie und Prophylaxe der Migräne. Leitlinien der Deutschen Migräne- und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008;27:933-949
6. Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Current Treatment Options in Neurology. 2008;10:20-29
7. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349 (Pubitemid 46184209)
8. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28:877-886
9. Schiff PL. Ergot and its alkaloids. Am J Pharm Educ 2006;70:98
10. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-1312 (Pubitemid 351550355)
11. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-1110 (Pubitemid 38298990)
12. Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verh Schweiz Naturforsch Ges 1918;101:190-191
13. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43:144-166 •• Excellent review on ergotamine and dihydroergotamine.
14. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119(Pt 1):249-256
15. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988;8:83-91
16. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11:165-168
17. Gröger D, Floss HG. Biochemistry of ergot alkaloids: achievements and challenges. In: Cordell GA, editor, The alkaloids. San Diego, Calif: Academic Press, Inc 1998. p. 172-218
18. Cvak L. Industrial production of ergot alkaloids. In: Kren V, Cval L, editors, Ergot, the genus claviceps Medicinal and aromatic plants. Amsterdam, The Netherlands: Harwood Academic Publishers; 1999. p. 373-409
19. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (tempo) inhaler. Headache 2008;48:355-367
20. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509-525 •• Excellent review on the mechanisms underlying primary headache disorders.
21. Millan MJ, Marin P, Bockaert J, la Cour CM. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008;29:454-464
22. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988;24:732-737 (Pubitemid 19019027)
23. Villalon CM, Centurion D, Willems EW, et al. 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 2004;484:287-290 (Pubitemid 38117222)
24. Hanoun N, Saurini F, Lanfumey L, et al. Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain. Br J Pharmacol 2003;139:424-434 (Pubitemid 36760375)
25. Schaerlinger B, Hickel P, Etienne N, et al. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol 2003;140:277-284 (Pubitemid 37249187)
26. Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther 1996;60:265-275 (Pubitemid 26354447)
27. Bobik A, Jennings G, Skews H, et al. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. Clin Pharmacol Ther 1981;30:673-679
28. Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982;13:785-790
29. Tfelt-Hansen P. Clinical pharmacology of ergotamine. An overview. In: Diener HC, Wilkinson M, editors, Drug-induced headache. Berlin: Springer-Verlag; 1988. p. 105-116
30. Müller-Schweinitzer E. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 1984;26:699-705 (Pubitemid 14074642)
31. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995-997 (Pubitemid 16098249)
32. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334-339 (Pubitemid 20361182)
33. Queiroz LP, Weeks RE, Rapoport AM, et al. Early and transient side effects of repetitive intravenous dihydroergotamine. Headache 1996;36:291-294
34. Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993;33:471-475 (Pubitemid 23332203)
35. Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med 1994;12:138-141 (Pubitemid 24112539)
36. Weisz MA, el-Raheb M, Blumenthal HJ. Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache 1994;34:371-373
37. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976-980 (Pubitemid 34008133)
38. Becker WJ, Riess CM, Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996;36:144-148 (Pubitemid 26116921)
39. Colman I, Brown MD, Innes GD, et al. Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med 2005;45:393-401 •• Systematic review and meta-analysis of clinical trials on parenteral use of dihydroergotamine. (Pubitemid 43181006)
40. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 1995;35:177-184
41. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285-1291
42. Treves TA, Kuritzky A, Hering R, Korczyn AD. Dihydroergotamine nasal spray in the treatment of acute migraine. Headache 1998;38:614-617 (Pubitemid 28481005)
43. Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia 1987;7:131-133
44. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. [see comment]. Neurology 1994;44:447-453
45. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361-365 (Pubitemid 26324028)
46. Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 2000;54:281-286 (Pubitemid 30386635)
47. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49:826-837 • First randomized, double-blind, placebo-controlled trial of the aerosol formulation of dihydroergotamine.
48. Shrewsbury SB, Kori SH, Miller SD, et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin 2008;24:1977-1985
49. Bousser MG, Chick J, Fuseau E, et al. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. Cephalalgia 1988;8:187-192
50. Pradalier A, Lanteri-Minet M, Geraud G, et al. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 2004;18:1149-1163 (Pubitemid 40007497)
51. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006;46(Suppl 4):S212-20 • Manuscript highlighting the use of dihydroergotamine under special conditions. (Pubitemid 44656906)
52. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-237
53. Silberstein SD, Young WB, Hopkins MM, et al. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache 2007;47:878-885
54. Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Current Pain Headache Rep 2005;9:363-367
55. Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994;34:578-580
56. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997;37(Suppl 1):S33-41
57. Müller-Schweinitzer E, Weidmann H. Basic pharmacologic properties. In: Berde B, Schild HO, editors, Ergot alkaloids and related compounds. Berlin: Springer-Verlag; 1978. p. 87-232
58. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working panel of the headache and facial pain section of the American academy of neurology. [see comment]. Neurology 1995;45:577-584
59. Malaquin F, Urban T, Ostinelli J, et al. Pleural and retroperitoneal fibrosis from dihydroergotamine. N Engl J Med 1989;321:1760
60. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, editors, The headaches, 3 edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 459-467
61. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment fo migraine In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, editors, The headaches, 3 edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 469-502
62. Katsarava Z, Holle D, Diener HC. Medication overuse headache. Curr Neurol Neurosci Rep 2009;9:115-119
63. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Current Pain Headache Rep 2003;7:55-62